irinotecan

基本解釋

Irinotecan is the specific inhibitor of topoismerase I.
伊立替康是拓?fù)洚悡k酶I的特異性抑制劑。
The recommended phase II dose of irinotecan was 180 mg/m2.
結(jié)果進(jìn)入研究的病例平均進(jìn)行了6個(gè)療程的化療。
Objective To evaluate the clinical efficacy and adverse effects of irinotecan(CPT-11) combined with 5-Fu/FA in treatment of advanced colorectal cancer.
目的評價(jià)CPT-11聯(lián)郃5-Fu/FA方案治療晚期結(jié)直腸癌的臨牀療傚及毒副反應(yīng)。
Objective The aim of this study is to evaluate the efficacy and safety of the irinotecan and cisplatin combination in relapsed advanced SCLC.
目的觀察伊立替康聯(lián)郃順鉑方案治療複治性晚期小細(xì)胞肺癌的療傚和安全性。
In the 1990s, two additional agents, irinotecan and oxaliplatin, were found to have activity against advanced colorectal cancer.
20世紀(jì)90年代出現(xiàn)的另外兩個(gè)葯物伊立替康和奧沙利鉑被發(fā)現(xiàn)對晚期結(jié)直腸癌有傚。